ArticleJournal of the National Cancer Institute2026
Advances and disparities in survival of childhood and adolescent cancers.
Article in Journal of the National Cancer Institute, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundWe analyzed trends in survival of children and adolescents diagnosed with cancer in the United States from 1975 to 2022 using the National Cancer Institute's (NCI) Surveillance, Epidemiology, and End Results (SEER) 8 and 17 databases. Our goal was to provide an updated overview of outcomes and highlight disparities to guide future research.
methodsData were obtained from the SEER 8 and 17 registries for patients diagnosed at 0 to 19 years. Overall survival (OS) was stratified by race/ethnicity, diagnosis, and population density. Temporal trends in five-year OS were evaluated using the NCI Joinpoint Regression Program. Kaplan-Meier survival curves with log-rank tests assessed survival differences across subgroups. Multivariable Cox proportional hazards models evaluated OS, adjusted for age, decade of diagnosis and race/ethnicity.
resultsA total of 52,165 patients were diagnosed with cancer in SEER 8, and 100,110 in SEER 17. Five-year OS for all cancers improved from 60% (95% CI:56 to 64%) in 1975 to 90% (95% CI : 88 to 91%) in 2017. Survival gains were greatest in acute lymphoblastic leukemia, with more modest improvements in solid tumors. Mortality beyond 20 years persisted for some cancers, including Hodgkin lymphoma. Survival differed significantly by race/ethnicity (p < 0.001), with non-Hispanic Black patients experiencing the lowest five-year OS across multiple cancers, even after adjusting for age/decade of diagnosis.
conclusionsSurvival for childhood and adolescent cancers has markedly improved over the past five decades, yet progress remains uneven across cancer types and race/ethnicity. Understanding drivers of disparities is essential to achieve equitable outcomes for all young cancer patients.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.